Coverage with Evidence Development/Access with Evidence Development
HTAi Special Interest Group on Conditional Coverage and Evidence Development for Promising Technologies
The board of Health Technology Assessment International (HTAi) has approved the formation of a Special Interest Group on Coverage with Evidence Development/Access with Development (CED/AED), facilitated by Kalipso Chalkidou and Sean Tunis. The group serves as a common forum for sharing and advancing work in this topic area. The SIG is currently considering the scope of interest which may include other forms of conditional reimbursement, such as risk sharing schemes.
Collection of Comments Received on Terminology and Definitions - updated 10.10.08
The comments collected from the Model Benefit Language working group on what whether the term (or terms) for Coverage with Evidence Development are sufficiently clear enough to be understood by the broad body of stake holders
CED survey form
This brief questionnaire is designed to obtain basic information about completed, ongoing or planned projects that involve “coverage with evidence development” (CED). CED is defined as any health policy initiative that links use of health care technology to a requirement for data collection, with the intent of informing future decision making.
Coverage with Evidence Development Forum
A discussion board on Coverage with Evidence Development Forum for the HTAi working group.
Issue Brief: Coverage for Evidence Development: A Conceptual Framework
Is there an alternative to a straightforward “yes” or “no” coverage decision by payers when the risks and benefits of an emerging technology1 remain unanswered? One alternative of interest to both U.S. and international payers is “Coverage for Evidence Development” (CED), which conditions coverage and payment for a technology on the collection of additional clinical evidence.
CMTP collaborates with NICE and AHRQ to convene an international discussion on "Managing Uncertainty in Healthcare" decision-making with a focus on Coverage with Evidence Development.
